Response by Hoque et al to Letter Regarding Article, "SUPPORT-AF II: Supporting Use of Anticoagulants Through Provider Profiling of Oral Anticoagulant Therapy for Atrial Fibrillation"

Laboni Hoque¹, David D McManus^{1

2}, Alok Kapoor^{1

2}

Affiliations

¹ Department of Medicine University of Massachusetts Medical School, Worcester, MA (L.H., D.D.M., A.K.).
² University of Massachusetts Memorial Health Care, Worcester, MA (D.D.M., A.K.).

Comment

Laboni Hoque et al. Circ Cardiovasc Qual Outcomes. 2020 May.

. 2020 May;13(5):e006671.

doi: 10.1161/CIRCOUTCOMES.120.006671. Epub 2020 May 7.

Laboni Hoque¹, David D McManus^{1

2}, Alok Kapoor^{1

2}

¹ Department of Medicine University of Massachusetts Medical School, Worcester, MA (L.H., D.D.M., A.K.).
² University of Massachusetts Memorial Health Care, Worcester, MA (D.D.M., A.K.).

No abstract available

Comment on

SUPPORT-AF II: Supporting Use of Anticoagulants Through Provider Profiling of Oral Anticoagulant Therapy for Atrial Fibrillation: A Cluster-Randomized Study of Electronic Profiling and Messaging Combined With Academic Detailing for Providers Making Decisions About Anticoagulation in Patients With Atrial Fibrillation.
Kapoor A, Amroze A, Vakil F, Crawford S, Der J, Mathew J, Alper E, Yogaratnam D, Javed S, Elhag R, Lin A, Narayanan S, Bartlett D, Nagy A, Shagoury BK, Fischer MA, Mazor KM, Saczynski JS, Ashburner JM, Lopes R, McManus DD. Kapoor A, et al. Circ Cardiovasc Qual Outcomes. 2020 Feb;13(2):e005871. doi: 10.1161/CIRCOUTCOMES.119.005871. Epub 2020 Feb 17. Circ Cardiovasc Qual Outcomes. 2020. PMID: 32063041 Clinical Trial.
Letter by Salata et al Regarding Article, "Utilization of Advanced Cardiovascular Therapies in the United States and Canada: An Observational Study of New York and Ontario Administrative Data".
Salata K, Hussain MA, Al-Omran M. Salata K, et al. Circ Cardiovasc Qual Outcomes. 2020 May;13(5):e006569. doi: 10.1161/CIRCOUTCOMES.120.006569. Epub 2020 May 5. Circ Cardiovasc Qual Outcomes. 2020. PMID: 32366115 No abstract available.

1. Kapoor A AA, Vakil F, Crawford S, Der J, Mathew J, Alper E, Yogaratnam D, Javed S, Elhag R, Lin A, Narayanan S, Bartlett D, Nagy A, Shagoury B, Fischer M, Mazor K, Saczynski J, Ashburner J, Lopes R, McManus D. SUPPORT-AF II: A Cluster-Randomized Study of Electronic Profiling and Messaging Combined with Academic Detailing for Providers Making Decisions about Anticoagulation in Patients With Atrial Fibrillation. Circulation Cardiovascular quality and outcomes. 2020;13:e005871. - PubMed
1. Guo Y, Lane DA, Wang L, Chen Y, Lip GYH on behalf of mAF-App II Trial Investigators. Mobile Health (mHealth) technology for improved screening, patient involvement and optimising integrated care in atrial fibrillation: The mAFA (mAF-App) II randomised trial. Int J Clin Pract. 2019;73:e13352. - PubMed
1. Cullen MW, Kim S, Piccini JP Sr., Ansell JE, Fonarow GC, Hylek EM, Singer DE, Mahaffey KW, Kowey PR, Thomas L, Go AS, Lopes RD, Chang P, Peterson ED, Gersh BJ and Investigators O-A. Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circulation Cardiovascular quality and outcomes. 2013;6:461–9. - PubMed
1. Shared Decision-Making: AFib 2gether Mobile App. Version 1.0.3 New York: Pfizer, Inc.; 2020.